BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 3931287)

  • 1. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia.
    Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD
    Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease.
    Gralnick HR; Rick ME
    N Engl J Med; 1983 Jun; 308(23):1393-5. PubMed ID: 6405274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danazol fails to increase factor VIII or IX levels in a double-blind crossover study of patients with haemophilia A and B.
    Nugent DJ; Bray GL; Counts RB; Clements MJ; Thompson AR
    Br J Haematol; 1986 Nov; 64(3):493-502. PubMed ID: 3098273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
    Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
    Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Danazol therapy in haemophilia.
    Heaton DC; Wyld PJ; Conder JL
    N Z Med J; 1986 Mar; 99(798):185-7. PubMed ID: 3517712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current clinical aspects in hemophilia treatment].
    Meili EO
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unintended benefit of anabolic steroid use in hemophilia B leiden.
    Rimmer EK; Seftel MD; Israels SJ; Houston DS
    Am J Hematol; 2012 Jan; 87(1):122-3. PubMed ID: 22038733
    [No Abstract]   [Full Text] [Related]  

  • 15. Factor VIII and IX variants. Relationship between haemophilia B M and haemophilia B+.
    Meyer D; Larrieu MJ; Obert B
    Eur J Clin Invest; 1971 Sep; 1(6):425-31. PubMed ID: 5121733
    [No Abstract]   [Full Text] [Related]  

  • 16. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of prothromboplastin factors (Factors VIII, IX, XI and XII)].
    Kagami M
    Nihon Rinsho; 1976; 34 suppl():2407-24. PubMed ID: 792517
    [No Abstract]   [Full Text] [Related]  

  • 19. [Determination of the deficient factor in hemophilic patients].
    Peñaloza-Santillán JA; Arias y Arias J; Resano-Pérez F
    Bol Med Hosp Infant Mex; 1975; 32(1):51-9. PubMed ID: 1109289
    [No Abstract]   [Full Text] [Related]  

  • 20. [The position of a vasopressin derivative ("DDAVP") in the treatment of haemophilia A (author's transl)].
    Blättler W; Jacky E; Müller M; Graf M; Meili E
    Ther Umsch; 1979 Apr; 36(4):330-3. PubMed ID: 377557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.